Close
Smartlab Europe
Achema middle east

News

EMA Follows FDA In Restricting Immune-Regulating Medicines

On October 28th, an advisory board to the European Medicines Agency advised restricting the use of a class of medications for inflammatory diseases due to a known association with side effects like cancer and heart attacks. The group recommended limiting...

Liquid relief for dental care

Huons Global expands anesthetics production with reliable cartridge filling technology from Syntegon. Nobody really likes to feel numb until they go see a dentist. Tooth extraction or drilling becomes a little less scary when topical anesthetics are used. One of...

China Releases The First COVID Vaccination That Is Inhaled

A new type of COVID-19 vaccination that is provided via inhalation rather than injection was this week introduced in Shanghai, the commercial city of China, in what is thought to be a first for the world. In September, Chinese authorities...

Omicron Subvariants Are Immune To Major Antibody Therapies

The White House issued a warning this week that HIV patients, kidney transplant recipients, and other immunocompromised people are particularly susceptible to COVID this winter because emerging omicron subvariants are impervious to important antibody therapy. Some of the key methods...

Biologics Offshore Likely To Grow In 2023, CPHI Study Claims

Part I of the CPHI Annual Report looks ahead at the potential for biologics outsourcing and contract manufacturing organisations (CMOs) in 2023 in advance of CPHI Frankfurt, the largest pharma event in the world, which will be held at...

In R&D, The UK Is Not Nearly As Far Ahead As Other Countries

According to a new report by IPPR, the UK's percentage of worldwide research and development (R&D) spending has decreased by 5% since 2014. Even while successive prime leaders, from David Cameron's jewel in the crown to Boris Johnson's science...

FDA Under Pressure To Alter Accelerated Approval Program

The necessity to update and alter the FDA's now-contentious rapid approval strategy is highlighted by the protracted, complicated FDA process to discontinue commercialization of medications that do not demonstrate safety and efficacy in mandated post-approval confirmatory studies. Over the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »